HIV
and Hepatitis.com Coverage of the 14th
Annual Conference on Retroviruses and Opportunistic Infections (14th CROI) February
25 - 28, 2007, Los Angeles, CA
Hepatitis
B Virus Plasma Dynamics in HIV-HBV Coinfected Patients Receiving Adefovir or Tenofovir
At the 14th
Conference on Retroviruses and Opportunistic Infections last month in Los
Angeles, researchers reported on a prospective study of 85 patients in the French
HIV-HBV Cohort Study. Patients were HBV treatment-naive at inclusion, except for
past or current use of 3TC (lamivudine;
Epivir) as part of an antiretroviral regimen. Baseline characteristics were
similar in the adefovir and tenofovir
arms, except for a different distribution of HBV
genotypes.
Results
•
Overall, during the first 6 months of therapy, HBV
DNA decreased by 1 log unit per month.
•
Individuals in the
tenofovir arm experienced a more rapid decline in HBV viral load compared with
the adefovir arm.
•
After 12 months of
therapy, HBV DNA had declined to a lower in the tenofovir arm.
•
Patients in the tenofovir
arm were more likely to experience decreased liver enzymes.
•
The same proportion
of patients in both arms achieved HBeAg seroconversion.
Conclusion
The
researchers concluded that HBV DNA declined less rapidly with adefovir than with
tenofovir, and that tenofovir was associated with better biochemical and antiviral
responses.
Hosp St Antoine, Paris, France; INSERM U707, Univ Pierre
and Marie Curie, Paris, France; Hosp Tenon, Paris, France; Hosp St Louis, Paris,
France; Hotel-Dieu, Lyon, France. Link
to study abstract and PDF of poster:
03/13/07
Reference K
Lacombe, P Y Boelle, J Gozlan, and others. Hepatitis B Virus Plasma Dynamics in
HIV/HBV-co-infected Patients: Significant Difference in the Anti-viral Activity
of Adefovir and Tenofovir. 14th Conference on Retroviruses and Opportunistic Infections.
Los Angeles, February 25-28, 2007. Abstract 945 (poster).
